NVOPharmaceuticals
FollowFollowingUnfollowFree · no card
Get what investors say about NVO next
1 investor call on NVO in the last 90 days (1 bullish, 0 bearish). Follow NVO free and new calls come to you in The Brief, our morning email, the day after we record them. This page shows them a week later.
or continue with Google ·
Who said what, and what NVO did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
Who’s talking about NVO
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-10-22 | Tim Seymour (Seymour Asset Mgmt)CIO, Seymour Asset Management | Bullish | CNBC (uncut) | Novo Nordisk's fundamental story remains intact and the stock is not being bought as a sector re-rating play… |
| 2026-04-21 | Alex KarnalCo-Founder & CIO, Braidwell | Bullish | Invest Like the Best | Oral Wegovy (semaglutide) launched and is already driving weekly new GLP-1 scripts from 200K to 300K as its… |
| 2026-01-13 | Karen Finerman (Metropolitan)CEO, Metropolitan Capital Advisors | Bullish | CNBC Fast Money Final Trade | Novo Nordisk holds a first-mover lead in the oral GLP-1 space, giving it a durable competitive advantage in… |
| 2026-01-05 | Carter WorthMarket technician, Worth Charting | Bullish | CNBC Fast Money Final Trade | Novo Nordisk has completed a bearish-to-bullish technical reversal, signaling a buy entry |
| 2025-12-23 | Tim Seymour (Seymour Asset Mgmt)CIO, Seymour Asset Management | Bullish | CNBC Fast Money Final Trade | Contrarian hold on Novo Nordisk despite near-term headwinds, sticking with the name as a final trade… |
| 2025-10-08 | Karen Fast Money PanelistCEO, Metropolitan Capital Advisors | Bullish | CNBC Fast Money Final Trade | Novo Nordisk offers exposure to the GLP-1/obesity drug space as an alternative to Eli Lilly, which the… |
| 2025-03-14 | Terry SmithFounder & CIO, Fundsmith | Bullish | Fundsmith LLP UK | Novo Nordisk holds ~two-thirds of the obesity drug market with 85% gross margins and 69% ROIC, and is… |
| 2024-09-26 | Terry SmithFounder & CIO, Fundsmith | Bullish | Financial Planner Life Podcast | Novo Nordisk is the one pharmaceutical holding within Fundsmith's medical-technology allocation, positioned… |
| 2024-02-18 | Freddie LaitManaging Partner & CIO, Latitude Investment Management | Bearish | Business Breakdowns | Exited a multi-year long position in Novo Nordisk purely on valuation grounds, while arguing GLP-1 drugs'… |
| 2024-02-15 | Terry SmithFounder & CIO, Fundsmith | Bullish | Killik & Co | Novo Nordisk's GLP-1 drugs (semaglutide) are showing efficacy well beyond weight loss — cardiovascular label… |
Notable options days
Sessions in the last 120 where NVO’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 5 of 120 sessions qualified.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-11-02 | ||||||
| 2026-09-24 | ||||||
| 2026-09-21 | ||||||
| 2026-08-04 | ||||||
| 2026-07-31 |
NVO on the Wheel
NVO did not pass our 1-month put test (V1, V2, V3); the Wheel shows its puts without calling one best.
The Wheel lists cash-secured puts on stocks after a 3% drop, with live quotes, the chance of assignment and each stock’s own history. Free to use; a free account lets you follow stocks, add your own and ask questions.
Decision support, not advice · questions put sellers ask us
Idea Scout
Following NVO? Every Sunday we read the tape so you don't have to — who's recommending what, where they agree, and who just changed their mind. One free email a week.
Free · double opt-in · unsubscribe in one click